Toll Free: 1-888-928-9744
Published: Feb, 2014 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Ranbaxy Laboratories Limited - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Ranbaxy Laboratories Limited - Product Pipeline Review - 2014', provides an overview of the Ranbaxy Laboratories Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Ranbaxy Laboratories Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Ranbaxy Laboratories Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Ranbaxy Laboratories Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Ranbaxy Laboratories Limited's pipeline products Reasons to buy - Evaluate Ranbaxy Laboratories Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Ranbaxy Laboratories Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Ranbaxy Laboratories Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Ranbaxy Laboratories Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ranbaxy Laboratories Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Ranbaxy Laboratories Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Ranbaxy Laboratories Limited Snapshot 5 Ranbaxy Laboratories Limited Overview 5 Key Information 5 Key Facts 5 Ranbaxy Laboratories Limited - Research and Development Overview 6 Key Therapeutic Areas 6 Ranbaxy Laboratories Limited - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Combination Treatment Modalities 10 Ranbaxy Laboratories Limited - Pipeline Products Glance 11 Ranbaxy Laboratories Limited - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Ranbaxy Laboratories Limited - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Ranbaxy Laboratories Limited - Drug Profiles 13 (arterolane maleate + piperaquine phosphate) 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 AE-9C90CB 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 AW-814141 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 RBx-0128 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 RBx-0597 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 RBx-10080307 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 RBx-14255 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 RBx-343E48F0 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Ranbaxy Laboratories Limited - Pipeline Analysis 21 Ranbaxy Laboratories Limited - Pipeline Products by Target 21 Ranbaxy Laboratories Limited - Pipeline Products by Route of Administration 23 Ranbaxy Laboratories Limited - Pipeline Products by Molecule Type 24 Ranbaxy Laboratories Limited - Pipeline Products by Mechanism of Action 25 Ranbaxy Laboratories Limited - Recent Pipeline Updates 27 Ranbaxy Laboratories Limited - Dormant Projects 28 Ranbaxy Laboratories Limited - Discontinued Pipeline Products 30 Discontinued Pipeline Product Profiles 30 RBx-10558 30 RBx-2258 30 Ranbaxy Laboratories Limited - Company Statement 31 Ranbaxy Laboratories Limited - Locations And Subsidiaries 33 Head Office 33 Other Locations & Subsidiaries 33 Ranbaxy Laboratories Limited - Key Manufacturing Facilities 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 39 Disclaimer 39
List of Tables Ranbaxy Laboratories Limited, Key Information 5 Ranbaxy Laboratories Limited, Key Facts 5 Ranbaxy Laboratories Limited - Pipeline by Indication, 2014 7 Ranbaxy Laboratories Limited - Pipeline by Stage of Development, 2014 8 Ranbaxy Laboratories Limited - Monotherapy Products in Pipeline, 2014 9 Ranbaxy Laboratories Limited - Combination Treatment Modalities in Pipeline, 2014 10 Ranbaxy Laboratories Limited - Phase III, 2014 11 Ranbaxy Laboratories Limited - Preclinical, 2014 12 Ranbaxy Laboratories Limited - Pipeline by Target, 2014 22 Ranbaxy Laboratories Limited - Pipeline by Route of Administration, 2014 23 Ranbaxy Laboratories Limited - Pipeline by Molecule Type, 2014 24 Ranbaxy Laboratories Limited - Pipeline Products by Mechanism of Action, 2014 26 Ranbaxy Laboratories Limited - Recent Pipeline Updates, 2014 27 Ranbaxy Laboratories Limited - Dormant Developmental Projects,2014 28 Ranbaxy Laboratories Limited - Discontinued Pipeline Products, 2014 30 Ranbaxy Laboratories Limited, Other Locations 33 Ranbaxy Laboratories Limited, Subsidiaries 34 Ranbaxy Laboratories Limited, Key Manufacturing Facilities 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.